Home NASDAQ: NVAX
7.24
Price1.12%   +0.08
 
loading

Novavax, Inc. Stock (NVAX) Latest News

thumbnail
pulisher
Seeking Alpha

Stocks To Watch: Eyes On Government Shutdown Drama, New Spinoffs And Auto Sector Updates

thumbnail
pulisher
The Motley Fool

Why Pfizer and BioNTech Stocks Zoomed Higher Today

thumbnail
pulisher
The Motley Fool

Does This Message From Moderna Mean Bad News for Novavax?

thumbnail
pulisher
The Motley Fool

You Can Pick Up These High-Risk, High-Reward Stocks for Less Than $10

thumbnail
pulisher
Zacks Investment Research

Moderna (MRNA) Receives CHMP Nod for Updated COVID Vaccine

thumbnail
pulisher
The Motley Fool

Why COVID Vaccine Demand Might Not Be That Strong

thumbnail
pulisher
The Motley Fool

Novavax Is a Step Behind, Again. Should You Be Worried?

thumbnail
pulisher
The Motley Fool

Up 20% in 1 Month, Is This Stock a Buy?

thumbnail
pulisher
Zacks Investment Research

The Zacks Analyst Blog Highlights Pfizer, BioNTech, Moderna and Novavax

thumbnail
pulisher
Zacks Investment Research

FDA Approves Pfizer & Moderna's New COVID Booster Vaccines

thumbnail
pulisher
Benzinga

Moderna, Pfizer Get FDA Nod For Omicron COVID Boosters While Novavax Waits

thumbnail
pulisher
MarketWatch

New Pfizer and Moderna COVID shots approved by FDA

thumbnail
pulisher
Zacks Investment Research

Novavax (NVAX) Up 36.8% Since Last Earnings Report: Can It Continue?

thumbnail
pulisher
Zacks Investment Research

Moderna (MRNA) Updated COVID Jab Effective Against Pirola Variant

thumbnail
pulisher
Zacks Investment Research

Stocks on the Mend: A Mean Reversion Duo

thumbnail
pulisher
The Motley Fool

This Down-on-Its-Luck Biotech Could Surge 150%, Wall Street Says. Should You Buy the Stock?

thumbnail
pulisher
The Motley Fool

Why Novavax Stock Rocketed 10% Higher Today

thumbnail
pulisher
Zacks Investment Research

Novavax (NVAX) Stock Increases 9% in a Month: Here's Why

thumbnail
pulisher
The Motley Fool

Coronavirus Cases Are on the Rise -- Should You Buy Vaccine Stocks?

thumbnail
pulisher
The Motley Fool

Should You Buy Novavax's Stock Before the FDA Approves Its New COVID Shot?

thumbnail
pulisher
Zacks Investment Research

Pfizer (PFE) & BioNTech Get CHMP Nod for Updated Covid-19 Jab

thumbnail
pulisher
The Motley Fool

Why Novavax Stock Was So Healthy on Monday

thumbnail
pulisher
Benzinga

Why NovoCure Are Trading Lower By Around 31%? Here Are Other Stocks Moving In Monday's Mid-Day Session

thumbnail
pulisher
MarketWatch

COVID is evolving quickly in white-tailed deer, study finds

thumbnail
pulisher
Benzinga

Jabil, Boston Scientific, Hersha Hospitality Trust And Other Big Stocks Moving Higher On Monday

thumbnail
pulisher
The Motley Fool

COVID Is Making a Comeback: Should You Buy These 2 Stocks?

thumbnail
pulisher
Zacks Investment Research

The Zacks Analyst Blog Highlights Regeneron Pharmaceuticals, Gilead Sciences, Novavax, Apellis Pharmaceuticals and Fulcrum Therapeutics

thumbnail
pulisher
The Motley Fool

Are These 2 Companies Next for Short Squeezes?

thumbnail
pulisher
Zacks Investment Research

Biotech Stock Roundup: REGN Up on Approval, APLS, NVAX Gain on Updates & More

thumbnail
pulisher
MarketWatch

Nvidia stock rises ahead of results, Foot Locker and Peloton tank, and other stocks on the move

thumbnail
pulisher
Zacks Investment Research

Novavax (NVAX) Updated COVID Jab Effective Against Eris Variant

thumbnail
pulisher
MarketWatch

Nvidia stock rises ahead of results, AMC shares slump and other stocks on the move.

thumbnail
pulisher
Zacks Investment Research

The Zacks Analyst Blog Highlights Moderna, BioNTech, Novavax and Pfizer

thumbnail
pulisher
The Motley Fool

Why Are Shares of Novavax Soaring Today?

thumbnail
pulisher
Zacks Investment Research

U.S. Govt to Urge Citizens to Get New COVID-19 Shots

thumbnail
pulisher
The Motley Fool

Why Moderna, BioNTech SE, and Novavax Surged Today

thumbnail
pulisher
MarketWatch

As COVID hospitalizations rise, Pfizer and Moderna say updated shots show promise against Eris variant

thumbnail
pulisher
MarketWatch

As COVID hospitalizations rise, Pfizer and Moderna say updated shots show promise against Eris variant

thumbnail
pulisher
Zacks Investment Research

Moderna (MRNA) Updated COVID Jab Effective Against Eris Variant

thumbnail
pulisher
The Motley Fool

Novavax Posted a Profit in Q2. Here's Why It Doesn't Matter

thumbnail
pulisher
MarketWatch

WHO names Eris a coronavirus variant of interest. Here’s what you need to know.

thumbnail
pulisher
MarketWatch

WHO names Eris a coronavirus variant of interest. Here’s what you need to know.

thumbnail
pulisher
The Motley Fool

2 Beaten-Down Stocks That Still Aren't Worth Buying

thumbnail
pulisher
The Motley Fool

Why Novavax Stock Blasted 8% Higher Today

thumbnail
pulisher
Benzinga

Why Krispy Kreme Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

thumbnail
pulisher
MarketWatch

WHO names Eris a COVID variant of interest. Here’s what you need to know.

thumbnail
pulisher
Benzinga

Alibaba, Illumina, CyberArk Software And Other Big Stocks Moving Higher On Thursday

thumbnail
pulisher
Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For August 9, 2023

thumbnail
pulisher
Zacks Investment Research

Novavax (NVAX) Q2 Earnings Beat, Stock Down 4% on '23 Sales Cut

thumbnail
pulisher
Benzinga

Bank Downgrades Trigger Stock Sell-Off; Treasuries, Dollar Rally Amid Safe-Haven Demand: What's Driving Markets Tuesday?

Novavax, Inc., together with its subsidiary, Novavax AB, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of recombinant nanoparticle vaccines and adjuvants. Its lead adjuvant is Matrix-M that is used to enable a vaccine to enhance the amplitude of the immune response and qualitatively change it, enhance its specificity to provide protection against related microorganisms, as well as allows immunization with much lower doses of antigen. The company develops respiratory syncytial (RSV) virus fusion protein nanoparticle vaccine candidate for infants via maternal immunization in Phase III clinical trial; older adults in Phase II clinical trial; and children six months to five years of age in Phase I clinical trial. Novavax, Inc. also develops NanoFlu vaccine, which is in Phase I/II clinical trial for treating seasonal influenza in older adults; and Ebola virus glycoprotein vaccine that is in Phase I clinical trial. Its preclinical programs include Zika virus; combination respiratory vaccine candidate to protect against RSV and seasonal influenza, as well as other infectious disease vaccine candidates. Novavax, Inc. was founded in 1987 and is headquartered in Gaithersburg, Maryland.
Cap:     |  Volume (24h):